848. Sulfamethoxazole/trimethoprim vs Fluoroquinolones for the Treatment of Stenotrophomonas maltophilia Bloodstream Infections
Session: Poster Abstract Session: Bacteremia and Endocarditis
Friday, October 9, 2015
Room: Poster Hall
Posters
  • Watson Sulfa vs fluoro_FINAL.pdf (395.3 kB)
  • Background: The drug of choice for Stenotrophomonas maltophilia (SM) infections is sulfamethoxazole/trimethoprim (S/T). Use of S/T may be limited due to allergy, intolerance, or resistance. Recent literature suggests levofloxacin may be a viable option for the treatment of SM bloodstream infections (BSI); however, clinical outcomes data are limited overall for SM BSI.  The objective of this study was to assess the clinical outcomes of patients with SM BSI that are treated with S/T compared to fluoroquinolones (FQ).

    Methods: Patients considered for study inclusion were > 18 years old, had at least one positive blood culture for SM between January 2004 and October 2014, hospitalized at Northwestern Memorial Hospital, and treated with at least 48 hours of FQ or S/T monotherapy. Baseline demographic variables including treatment used were assessed to determine their impact on clinical outcomes. Stepwise multivariate regression was performed to assess predictors of mortality. 

    Results: 54 patients were included in the analysis (n= 22 FQ [levofloxacin n=4, moxifloxacin n=6, ciprofloxacin n=11] and n=32 S/T). Baseline characteristics were similar between treatment groups. Mortality rates between FQ and S/T differed numerically but not statistically (n=3, 13.6% [n=3 moxifloxacin and n=0 for levofloxacin and ciprofloxacin] and n=10, 31.3% respectively, p=0.20). Time to death from positive culture also differed numerically between treatment groups (FQ n=3 days, IQR 11-64; S/T n=12.5 days, IQR 12-36; p=0.61). Bivariate analysis revealed modified APACHE II, septic shock, mechanical ventilation, organ dysfunction, broad spectrum antibiotics prior to culture, and concomitant positive respiratory cultures with SM as positive predictors of mortality (p<0.05 for all). In a multivariate analysis, modified APACHE II score (OR 1.4, 95% CI 1.1-1.8) and broad spectrum antibiotics prior to culture (OR 8, 95% CI 1.3-49.8) remained as significant predictors of mortality.

    Conclusion: FQ treated patients showed similar clinical outcomes to those treated with S/T for SM BSI. Multivariate analyses indicated that factors other than treatment had an impact on clinical outcomes. Further study is required.

    Luke Watson, PharmD1, John Esterly, PharmD1,2, Michael Postelnick, RPh1, Arturo Aguirre, BS1,3 and Milena Mclaughlin, PharmD, MSc1,4, (1)Northwestern Memorial Hospital, Chicago, IL, (2)Chicago State University College of Pharmacy, Chicago, IL, (3)University of Illinois at Chicago, Chicago, IL, (4)Midwestern University Chicago College of Pharmacy, Downers Grove, IL

    Disclosures:

    L. Watson, None

    J. Esterly, BioCryst Pharmaceuticals: Served on Advisory Board , Consulting fee

    M. Postelnick, None

    A. Aguirre, None

    M. Mclaughlin, BioCryst Pharmaceuticals: Served on Advisory Board , Consulting fee

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.